Evidence map›Paper›PMID 29695021›Full record

ArticleThrombosis and haemostasis2018

Pre-Clinical Model to Study Recurrent Venous Thrombosis in the Inferior Vena Cava.

Elizabeth A Andraska, Catherine E Luke, Megan A Elfline, Samuel P Henke, Siddharth S Madapoosi, Allan K Metz, Megan E Hoinville, Thomas W Wakefield, Peter K Henke, Jose A Diaz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis and haemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Transforming Growth Factors in Venous Thrombus Formation and Resolution.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  2. Review
  3. Editorial: Highlights in Thrombosis: 2021.Frontiers in cardiovascular medicine · 2022
    Article
  4. Review
  5. Insights from experimental post-thrombotic syndrome and potential for novel therapies.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Elizabeth A AndraskaDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Catherine E LukeDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Megan A ElflineDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Samuel P HenkeDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Siddharth S MadapoosiDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Allan K MetzDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Megan E HoinvilleDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Thomas W WakefieldDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Peter K HenkeDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Jose A DiazDepartment of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, University of Michigan, Ann Arbor, Michigan, United States.
Michigan United · USUniversity of Michigan–Ann Arbor · US

Funding

The Role of IL-6 in Experimental Post Thrombotic SyndromeR01HL132988 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HENKE, PETER K · 2016 to 2019
$1.9M
NHLBI NIH HHS R01 HL132988
6 · The paper itself

Abstract

backgroundPatients undergoing deep vein thrombosis (VT) have over 30% recurrence, directly increasing their risk of post-thrombotic syndrome. Current murine models of inferior vena cava (IVC) VT model host one thrombosis event.

objectiveWe aimed to develop a murine model to study IVC recurrent VT in mice. MATERIALS AND

methodsAn initial VT was induced using the electrolytic IVC model (EIM) with constant blood flow. This approach takes advantage of the restored vein lumen 21 days after a single VT event in the EIM demonstrated by ultrasound. We then induced a second VT 21 days later, using either EIM or an IVC ligation model for comparison. The control groups were a sham surgery and, 21 days later, either EIM or IVC ligation. IVC wall and thrombus were harvested 2 days after the second insult and analysed for IVC and thrombus size, gene expression of fibrotic markers, histology for collagen and Western blot for citrullinated histone 3 (Cit-H3) and fibrin.

resultsUltrasound confirmed the first VT and its progressive resolution with an anatomical channel allowing room for the second thrombus by day 21. As compared with a primary VT, recurrent VT has heavier walls with significant up-regulation of transforming growth factor-β (TGF-β), elastin, interleukin (IL)-6, matrix metallopeptidase 9 (MMP9), MMP2 and a thrombus with high citrullinated histone-3 and fibrin content.

conclusionExperimental recurrent thrombi are structurally and compositionally different from the primary VT, with a greater pro-fibrotic remodelling vein wall profile. This work provides a VT recurrence IVC model that will help to improve the current understanding of the biological mechanisms and directed treatment of recurrent VT.

Indexed as

Disease Models, AnimalAnimalsCells, CulturedElastinElectrolytesFibrosisHumansInterleukin-6Matrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMice, Inbred C57BLPostthrombotic SyndromeRecurrenceRiskTransforming Growth Factor betaElastinElectrolytesInterleukin-6Matrix Metalloproteinase 2Matrix Metalloproteinase 9Transforming Growth Factor beta

Identifiers

PMID29695021
PMCPMC6527429
OpenAlexW2801096113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.